Clinical Trials Arena October 11, 2024
CancerVision achieved 100% concordance compared to Illumina’s widely used TSO500 assay, detecting 498 variants in 49 patients.
US company Inocras has announced the successful clinical validation of its CancerVision target enhanced whole genome sequencing (TE-WGS) technology.
TE-WGS is an advanced genomic testing method that combines WGS with targeted enrichment techniques to focus on specific regions of the genome known to be clinically relevant in cancer. The approach doesn’t sequence the entire genome – like traditional WGS – but instead prioritises areas with high clinical value.
In comparison with Illumina’s widely used TSO500 assay, CancerVision achieved 100% concordance, detecting 498 variants identified by TSO500 in a cohort of 49 cancer patients. Additionally, CancerVision differentiated between germline (44.8%) and somatic...
Today's Sponsors
Today's Sponsor